Skip to content
    CORT
    Earnings call· Dec 2025(Q4 FY25)

    CORCEPT THERAPEUTICS Q4 FY25 earnings call CORT

    Feb 24, 2026 Source

    Executive summary

    Corcept Therapeutics Q4 FY25 — Strong Korlym Growth Offset by Relacorilant CRL, Oncology Pipeline Progresses

    Corcept Therapeutics reported strong Q4 FY25 results driven by its Cushing's Syndrome business, which experienced a surge in demand and successfully transitioned to a new pharmacy vendor. However, the FDA's unexpected Complete Response Letter for relacorilant in Cushing's syndrome presents a near-term challenge, while the company plans to appeal a court ruling against its Korlym patents. The oncology pipeline showed significant progress with positive Phase III ROSELLA data and a PDUFA date set for July, alongside advancing studies in MASH and ALS.

    Highlights

    4
    • Full-year 2025 revenue reached $761 million, up from $675 million in the prior year.

    • Cushing's Syndrome business saw a 61% increase in new prescriptions and a 37% increase in tablets delivered in 2025.

    • ROSELLA Phase III trial in platinum-resistant ovarian cancer met both primary endpoints, showing a 35% reduction in risk of death (HR 0.65, p=0.0004) and 4.1 months longer median overall survival.

    • DAZALS trial for ALS showed an 84% reduction in risk of death for patients receiving 300mg dazucorilant (p=0.0009).

    Concerns

    3
    • FDA issued a Complete Response Letter (CRL) for relacorilant as a treatment for Cushing's syndrome, despite positive GRACE trial data.

    • Net income for full year 2025 decreased to $99.7 million from $141.2 million in the prior year.

    • Federal Circuit Court ruled against Corcept in its lawsuit to stop Teva Pharmaceuticals from marketing a generic version of Korlym.

    Guidance & targets

    8
    CategoryTargetConfidence
    Full-year revenue
    $900 million to $1 billion
    high materiality
    High
    Cushing's syndrome business annual revenue
    at least $2 billion
    high materiality
    High
    Relacorilant (platinum-resistant ovarian cancer) PDUFA date
    July 11 of this year
    high materiality
    High
    MOMENTUM trial findings presentation
    next month
    medium materiality
    High
    ROSELLA full results presentation
    April
    medium materiality
    High
    Other new oncology trials results
    by the end of 2027
    medium materiality
    High
    DAZALS Phase III study start
    by midyear
    medium materiality
    High
    MONARCH trial outcome
    by year-end
    medium materiality
    High

    Segment performance

    1
    SegmentRevenueYoYQoQMargin
    Cushing's Syndrome Business
    Experienced a surge in demand in 2025, with record new prescriptions and first-time prescribers. Pharmacy vendor transition caused disruption but is now complete, leading to improved performance and confidence in future growth. Long-term target of at least $2 billion in annual revenue by end of decade.
    New prescriptions growth: 61% YoYTablets delivered growth: 37% YoYAG share of prescriptions: 75% (end of 2025), 78% (currently)New patient starts: on track for monthly record in February

    Operational metrics

    14
    Cash and investments balance
    $532 million
    as of December 31, 2025

    Reflects acquisition of $245 million worth of common stock.

    Net income
    $99.7 milliondown from $141.2 million in prior year
    FY25

    Full year net income.

    New prescriptions growth
    61%
    2025

    Increase in new prescriptions for medications.

    Tablets delivered growth
    37%
    2025

    Increase in tablets delivered, indicating a gap with new prescription growth due to pharmacy capacity.

    AG net price discount
    30%
    current

    Consistent discount since the launch of the AG.

    AG share of prescriptions
    75%
    end of 2025

    Volume shifted from Korlym to AG prescriptions.

    AG share of prescriptions
    78%
    currently

    Expected to stabilize with potential slight increase.

    Hypercortisolism prevalence in resistant diabetes
    24%
    CATALYST trial

    Prevalence phase of the CATALYST trial screened 1,000 patients.

    HbA1c mean decrease (Korlym)
    1.47%vs 0.17% for placebo
    24 weeks

    In patients with uncontrolled diabetes and hypercortisolism.

    Relacorilant (platinum-resistant ovarian cancer) risk reduction of death
    35%vs nab-paclitaxel alone
    ROSELLA trial

    One of the dual primary endpoints met in the Phase III ROSELLA trial.

    Relacorilant (platinum-resistant ovarian cancer) median overall survival extension
    4.1 monthslonger than nab-paclitaxel monotherapy
    ROSELLA trial

    One of the dual primary endpoints met in the Phase III ROSELLA trial.

    Relacorilant (platinum-resistant ovarian cancer) overall survival extension at 75th percentile
    8 monthslonger than nab-paclitaxel alone
    ROSELLA trial

    Significant number of patients responded even better.

    Dazucorilant (ALS) risk reduction of death
    84%vs placebo
    1 year

    Results from the 249-patient double-blind, placebo-controlled Phase II DAZALS trial.

    ALT rises in ROSELLA trial
    half the amountvs nab-paclitaxel alone arm
    ROSELLA trial

    Indicates no added toxicity and actually a reduction in ALT rises with the combination.

    Industry KPIs

    8
    MetricValueDetails
    Peak sales guidanceat least $2 billionUSD
    Prescription volume61% increase in new prescriptions; 37% increase in tablets delivered%
    EPS revenue guidance$900 million to $1 billionUSD
    Pipeline clinical milestonesMultiple
    Regulatory approvals filingsCRL for Relacorilant (Cushing's); PDUFA July 11, 2026 for Relacorilant (platinum-resistant ovarian cancer)
    Price volume mix decomposition30%%
    Glp 1 incretin franchise metrics24%%
    Clinical trial efficacy safety data35% reduction in risk of death (ROSELLA); 84% reduction in risk of death (DAZALS)%

    Deals & partnerships

    2
    Teva PharmaceuticalsPatent infringement lawsuit

    Federal Circuit Court of Appeals ruled against Corcept in its lawsuit to stop Teva from marketing a generic version of Korlym. Corcept plans to appeal.

    ShareholdersStock repurchase program$245 million

    Acquisition of common stock pursuant to the stock repurchase program in 2025.

    Risks & headwinds

    4
    FDA Complete Response Letter for relacorilant in Cushing's syndromenear-term

    CRL issued

    Mitigation: Plan to meet with FDA in April to understand reasoning; potential options include NDA resubmission, formal appeal, or new study.

    Teva Pharmaceuticals patent lawsuit rulingongoing

    Federal Circuit Court ruled against Corcept

    Mitigation: Company plans to appeal the decision.

    Pharmacy vendor capacity issuesresolved (as of February 2026)

    61% increase in new prescriptions vs 37% increase in tablets sold in 2025

    Mitigation: Transitioned to a new specialty pharmacy (Curant) with greater capacity; transition work has subsided, and performance is improving.

    Potential pricing pressures and discounting for Korlymremainder of 2026

    AG net price about 30% discount on WAC; AG share currently 78%

    Mitigation: Built into 2026 guidance; AG share is essentially stabilized.

    What to watch in Q1 FY26

    5

    Relacorilant (Cushing's) FDA meeting outcome

    April 2026
    CurrentCRL issued
    TargetClear path forward (resubmission, appeal, or new study)

    Why it matters

    This will determine the future regulatory path and potential market entry for relacorilant in Cushing's syndrome, a key growth driver.

    Our priority is to make relacorilant available to patients as quickly as possible. We will meet with the FDA in April to better understand its thinking. Outcomes from that meeting range from resubmission of our NDA, perhaps including additional analyses from our NDA's rich data set to a filing of a formal appeal with the FDA's Office of New Drugs to deciding we need to conduct a new study.

    Q&A highlights

    6

    Analyst asked for more detailed thoughts on the FDA's CRL for relacorilant in Cushing's syndrome, suggesting the agency 'moved the goalpost' and seeking clarification on the gap between the company's and FDA's views.

    Management stated they believe the FDA 'missed the mark' as their data met approval hurdles and compared favorably to other approved drugs. They acknowledged a 'daylight' between their position and the FDA's, particularly regarding an analysis performed by the agency that the company couldn't replicate. They plan to meet with the FDA in April to understand their decision.

    I mean I think the -- again, I think that without sort of parsing the CRL line by line, there are things in it that are sort of curious and hard to follow. For example, leading with -- the acknowledge is right out of the gate that our pivotal trial met its primary endpoint for instance.

    asked by David Amsellem · answered by Gary Robb

    2 min read5 chapters

    Detailed Narrative

    01

    FDA Complete Response Letter for Relacorilant in Cushing's Syndrome

    Corcept Therapeutics received an unexpected Complete Response Letter (CRL) from the FDA for relacorilant as a treatment for Cushing's syndrome. Management expressed surprise, citing that the pivotal GRACE trial met its primary endpoint (p=0.02) and was supported by confirmatory evidence from the GRADIENT trial. They also highlighted relacorilant's benefits in hypertension and other Cushing's symptoms, along with a favorable safety profile compared to existing treatments. The company plans to meet with the FDA in April to understand the agency's thinking, with potential outcomes ranging from NDA resubmission to a formal appeal or conducting a new study.

    02

    Korlym Commercial Performance and Pharmacy Transition

    The Cushing's Syndrome business experienced a surge in demand in 2025, with a record number of new prescriptions and first-time prescribers. However, the company faced challenges with its previous pharmacy vendor's capacity, leading to a gap between a 61% increase in new prescriptions and a 37% increase in tablets sold. A transition to a new specialty pharmacy, Curant, began in October and was completed in February. Management is confident in the new pharmacy's capabilities, citing improved performance metrics and expecting record new patient starts in February.

    03

    CATALYST and MOMENTUM Trial Impact on Cushing's Syndrome Business

    The landmark CATALYST trial demonstrated that 24% of patients with uncontrolled diabetes (even on GLP-1s) had hypercortisolism, and treatment with Korlym led to significant improvements in HbA1c (1.47% mean decrease vs 0.17% for placebo), weight, and waist circumference. These findings are transforming medical practice and are expected to drive increased screening and treatment for Cushing's syndrome. The MOMENTUM trial, examining hypercortisolism prevalence in resistant hypertension, is fully enrolled, with results expected next month, potentially providing similar paradigm-shifting insights.

    04

    ROSELLA Phase III Data and Oncology Strategy

    The Phase III ROSELLA trial for relacorilant in platinum-resistant ovarian cancer met both dual primary endpoints, showing a 35% reduction in the risk of death (HR 0.65, p=0.0004) and a 4.1-month increase in median overall survival. The safety profile was comparable to nab-paclitaxel alone, with a reduction in ALT rises in the combination arm. Full results will be presented at the SGO meeting in April. Management believes relacorilant could become a new standard of care, with a PDUFA date set for July 11. The company is also evaluating relacorilant in other solid tumors and in combination with other anticancer therapies, with results expected by the end of 2027.

    05

    Broader Pipeline Progress in MASH and ALS

    Corcept is advancing its pipeline beyond Cushing's syndrome and ovarian cancer. The Phase IIb MONARCH study for relacorilant in Metabolic Dysfunction-Associated Steatohepatitis (MASH) is fully enrolled, with results anticipated by year-end. For ALS, the DAZALS trial with dazucorilant showed an 84% reduction in the risk of death. A dose titration study is underway to improve GI tolerability, with a pivotal trial planned to start by midyear. The company continues to discover and develop new cortisol modulators for various indications.

    AI-generated summary of the company’s earnings call. Not investment advice.